Biotech industry leaders publish Healthcare Manifesto and set out policy challenges (link)

September 23, 2005

Brussels, 22 Sep 2005

Introducing you to healthcare biotechnology

An overview of EU policies in biotechnology: the Lisbon agenda and beyond

European biotech industry leaders publish a new Healthcare Manifesto. More than 250 million patients to date have benefited from biotech medicines to treat or prevent heart attacks, Multiple Sclerosis, breast cancer, cystic fibrosis, leukaemia and other diseases including rare disorders. But many patients do not have access to treatments and many diseases are still untreated.

The manifesto, published by EuropaBio sets out seven key policies to meet the healthcare innovations expected over the next few years to meet unmet medical needs.

  • The role of economic evaluation of biotechnology medicines and emerging technologies

  • Biosimilar Medicinal Products: raising the bar of quality and safety - a public health perspective

  • Orphan Drugs: completing a European dream

  • Reaching for new medical frontiers with emerging cell & tissue engineered products

  • Bioethics as an invaluable component in today's healthcare industry

  • Diagnosis and innovative medicines go hand in hand: towards targeted therapies, the role of genetics and pharmacogenetics

Biotech to biotech: where size matters: creating a friendly environment for SME's and the biotech industry

Full text of manifesto

Item source: Previous Item Back to Titles Print Item

Please login or register to read this article.

Register to continue

Get a month's unlimited access to THE content online. Just register and complete your career summary.

Registration is free and only takes a moment. Once registered you can read a total of 3 articles each month, plus:

  • Sign up for the editor's highlights
  • Receive World University Rankings news first
  • Get job alerts, shortlist jobs and save job searches
  • Participate in reader discussions and post comments

Have your say

Log in or register to post comments